Skip to content

Microbiological and Clinical Effects of Pre- and Probiotics in Systematic Periodontal Therapy

Microbiological and Clinical Effects of Pre- and Probiotics in Systematic Periodontal Therapy - ProParo

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00038348
Enrollment
60
Registered
2025-11-06
Start date
2024-11-12
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K05.3

Interventions

Group 1: Participants receive standard non-surgical periodontal therapy (scaling and root planing) together with a probiotic supplement (GUM® PerioBalance®, Sunstar Deutschland GmbH, Schönau, Germany)

Sponsors

Universitätsklinikum Heidelberg, Abteilung für Zahnerhaltungskunde
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosed periodontitis, localized or generalized, stage III or IV Scheduled for systematic periodontal therapy Ability to give informed consent and signed informed consent form Agreement with data protection regulations

Exclusion criteria

Exclusion criteria: Age < 18 years Missing consent or lack of agreement with data protection Cognitive impairment or inability to give informed consent Known systemic disease affecting the oral microbiome (e.g. diabetes mellitus) Pregnancy or breastfeeding Periodontitis as a manifestation of a systemic disease Requirement for adjunctive antibiotic therapy during periodontal treatment (e.g. endocarditis risk, immunosuppression, prior head-neck irradiation) Bleeding tendency or current anticoagulant therapy Use of corticosteroids or immunosuppressive medication Use of calcium channel blockers Severe systemic or infectious disease (e.g. HIV) Acute infections Alcohol or drug abuse Subgingival instrumentation within the last 6 months Antibiotic use within the last 3 months Intake of pro- or prebiotics within the last 3 months Participation in another dental study involving mechanical or drug therapy within the last 6 months Regular use of antiseptic mouth rinses Strict dietary regimes (e.g. vegan or ketogenic diet) Chronic inflammatory bowel disease

Design outcomes

Primary

MeasureTime frame
Change in the composition and relative abundance of microbial species in the oral microbiome (supragingival and subgingival) between baseline and three months after therapy, assessed by 16S rDNA and metagenomic sequencing.

Secondary

MeasureTime frame
Change in clinical periodontal parameters: probing pocket depth (PPD), clinical attachment level (CAL), bleeding on probing (BOP), gingival bleeding index (GBI), plaque control record (PCR). • Change in overall oral health status (DMFT index). • Change in nutritional quality assessed by validated questionnaires (DEGS and MEDAS). • Change in perceived stress level assessed by the Perceived Stress Scale (PSS). • Change in level of physical activity assessed by the International Physical Activity Questionnaire (IPAQ). • Demographic, socioeconomic, and health-related background data collected via structured questionnaires and anamnesis.

Countries

Germany

Contacts

Public ContactDiana Wolff

Universitätsklinikum Heidelberg

diana.wolff@med.uni-heidelberg.de+406221566002

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026